Everest Medicines Signs MOU with CR Pharma to Form mRNA Company
publication date: Apr 8, 2022
Shanghai Everest Medicines signed a memorandum of understanding with China Resources Pharmaceutical Group to form a partnered mRNA company. In September 2021, Everest announced a $500 million deal with Providence Pharma, a Canadian mRNA company, to develop Providence’s mRNA products in China including a clinical stage mRNA COVID-19 vaccine. The new mRNA partnership with CR Pharma will be built on Everest’s Providence-based portfolio, which includes several COVID vaccines and mRNA oncology candidates. Everest, which will be the controlling shareholder of the mRNA Co., did not disclose financial details. More details....
Stock Symbols: (HK 1952) (HK: 3320)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.